Is de Commissie op de hoogte van de nieuwe Harvard studie Use of di(2-ethylhexyl) phtalate containing medical products and urinary levels of mono(2-ethylhexyl) phtalate in neonatal intensive care unit infants, waaruit af te leiden valt dat pasgeboren baby's op intensive care-afdelingen hoge DEHP-niveaus in hun urine hadden?
Is the Commission aware of the new Harvard study 'Use of di(2-ethylhexyl) phthalate containing medical products and urinary levels of mono(2-ethylhexyl) phthalate in neonatal intensive care unit infants', which suggested that newborn babies in intensive care units had high levels of DEHP in their urine?